Back to Journals » Drug Design, Development and Therapy » Volume 13

A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson’s disease, in healthy volunteers

Total article views   HTML views PDF downloads Totals
7,359 Dovepress* 6,430+ 1,172 7,602
PubMed Central* 929 229 1,158
Totals 7,359 1,401 8,760
*Since 29 March 2019
Total mentioned Facebook Delicious Reddit Twitter Others
2 0 0 0 1 1

View citations on PubMed Central and Google Scholar